Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Top brokers name 3 ASX 200 shares to buy today
Speculative
3 exciting small cap ASX healthcare shares to watch
Share Market News
12 top ASX dividend shares to buy in June 2020
Growth Shares
3 excellent ASX growth shares to invest $3,000 into right now
Share Market News
3 safe and strong ASX 50 shares to buy right now
⏸️ ASX Shares
3 quality ASX 200 shares to buy and hold until at least 2030
⏸️ ASX Shares
10 ASX 200 shares that are fit for the Queen
Share Market News
Top brokers name 3 ASX 200 shares to sell today
⏸️ ASX Shares
Where to invest $10,000 into ASX shares immediately
⏸️ ASX Shares
Tax planning for ASX 200 investors
Growth Shares
3 top ASX growth shares to buy with $3,000
How to invest
How to become a millionaire with a $5,000 investment in ASX 200 shares each year
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
